Clover Health Investments Corp CLOV.OQ CLOV.O is expected to show a rise in quarterly revenue when it reports results on November 4 for the period ending September 30 2025
The Jersey City New Jersey-based company is expected to report a 42.3% increase in revenue to $471.091 million from $330.99 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
LSEG's mean analyst estimate for Clover Health Investments Corp is for a loss of 3 cents per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Clover Health Investments Corp is $3.00, about 15.7% below its last closing price of $3.47
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | -0.03 | -0.03 | -0.02 | Beat | 27.3 |
Mar. 31 2025 | -0.07 | -0.06 | 0.00 | Beat | 100 |
Dec. 31 2024 | -0.06 | -0.06 | -0.04 | Beat | 38.5 |
Sep. 30 2024 | -0.04 | -0.04 | -0.02 | Beat | 50 |
Jun. 30 2024 | -0.04 | -0.05 | 0.01 | Beat | 120.5 |
Mar. 31 2024 | -0.06 | -0.07 | -0.04 | Beat | 44.7 |
Dec. 31 2023 | -0.10 | -0.14 | -0.14 | Met | -0.5 |
Sep. 30 2023 | -0.10 | -0.11 | -0.09 | Beat | 14.8 |
This summary was machine generated November 1 at 00:14 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)